Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir.

被引：0
|
作者：
Fallah, T. [1 ]
Logan, A. [2 ]
Garcia, L. Beltran [3 ]
Bowman, L. [2 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Tampa Gen Hosp, Tampa, FL 33606 USA
[3] Tampa Gen Hosp, Florida Kidney Phys, Tampa, FL 33606 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A326
引用
下载
收藏
页码：722 / 722
页数：1
相关论文
共 50 条
  • [31] Delayed Valganciclovir Initiation and the Incidence of Cytomegalovirus Infection in Liver Transplant Recipients
    Shaikh, S.
    Kawewat-Ho, P.
    Genyk, Y.
    Sher, L.
    Kahn, J.
    Rivera, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 623 - 623
  • [32] Cytomegulo virus (CMV) disease progression in two kidney transplant recipients under treatment with valganciclovir.
    Mogilishetty, G
    Barone, G
    Kumar, J
    Abul-Ezz, S
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 773A - 773A
  • [33] Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients.
    Anders, S.
    Freeman, A.
    Hutchinson, L.
    Kaszubski, U.
    Janusek, M.
    Hooter, A.
    Raymond, D.
    Nguyen, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 1075 - 1075
  • [34] Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients
    Luan, F. L.
    Chopra, P.
    Park, J.
    Norman, S.
    Cibrik, D.
    Ojo, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3673 - 3675
  • [35] Low dose valganciclovir in liver transplant recipients.
    Dupuis, R
    Harris, M
    Andreoni, K
    Gerber, D
    Conoley, R
    Fair, J
    VanBeuge, D
    Johnson, M
    Watson, R
    Shrestha, R
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 167 - 167
  • [36] Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
    Wong, Diana D.
    van Zuylen, Wendy J.
    Novos, Talia
    Stocker, Sophie
    Reuter, Stephanie E.
    Au, Jane
    Foster, Charles S. P.
    Day, Richard O.
    Horvath, Andrea R.
    Endre, Zoltan
    Rawlinson, William D.
    MICROBIOLOGY SPECTRUM, 2022, 10 (03):
  • [37] INCIDENCE OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS AND REDUCED TACROLIMUS DOSES
    Campos, Juliana Bastos
    Colares, Vinicius Sardao
    Souza, Glaucio Da Silva
    De Souza, Marcio Luiz
    De Rezende Moreira, Paulo Rogerio
    Ferreira, Sebastiao
    Fernandes, Guilherme Cortes
    Ferreira, Gustavo
    TRANSPLANT INTERNATIONAL, 2017, 30 : 88 - 88
  • [38] Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis
    Stevens, D. R.
    Sawinski, D.
    Blumberg, E.
    Galanakis, N.
    Bloom, R. D.
    Trofe-Clark, J.
    TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (02) : 163 - 173
  • [39] Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients
    Li, Yihan
    Pluckrose, Dawn M.
    Patolia, Roshani
    Arnouk, Serena
    Dubrovskaya, Yanina
    Papadopoulos, John
    Jonchhe, Srijana
    ANNALS OF PHARMACOTHERAPY, 2024,
  • [40] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad
    TRANSPLANT INTERNATIONAL, 2019, 32 : 295 - 295
12345